Patent Yard Sign in
Canadian application, no grantCanada

Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this method

CA 2397729 A1 · Owner: I.D.M. Immuno-Designed Molecules · Inventors: Abastado, Jean-Pierre; Machy, Patrick; Serre, Karine

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

The invention relates to an opsonized micro-particle complex comprising: a micro-particular vector encapsulating at least one antigen and at least one , antibody or fragment thereof with said antibody being a human or humanized antibody or an antibody binding to human FcR with substantially the same affinity and avidity as the ones of a human antibody and with said antibody or fragment thereof having the carboxy terminal end of its Fc portion external with respect to the opsonized micro particle complex.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed December 20, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 20, 2020.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 20, 2022.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledDecember 20, 2000
GrantedNo grant recorded
Term endedDecember 20, 2020
Patent numberCA 2397729 A1
Classification (IPC)A61K39/00 +2 more

Timeline

Timeline From CIPO dates

2001200320052007200920112013201520172019Application filedDec 20, 2000Term endedDec 20, 2020

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.